Acalabrutinib Vs Ibrutinib (updated 2024-12-01)

Overcoming challenges with targeted therapies for CLL highrisk mutations and BTKi resistance

Duration: 3:09
47 views | 1 month ago

Acalabrutinib CALQUENCE®

Duration: 6:08
47 views | 9 months ago

The impact of acalabrutinib treatment by line of therapy in patients with CLL

Duration: 1:44
162 views | 4 months ago

An overview of clinical trials investigating BTK inhibitors and degraders in MCL

Duration: 1:22
77 views | 1 month ago

Assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with Bcell malignancies

Duration: 1:09
145 views | 4 months ago

Mechanism of Action for Covalent and NonCovalent BTKi

Duration: 2:18
27 views | 2 weeks ago

Ibrutinib plus rituximab in symptomatic Japanese patients with Waldenströms macroglobulinemia

Duration: 1:06
62 views | 1 month ago

Dr Fürstenau on Safety Data From the GAIACLL13 Trial in Untreated CLL

Duration: 3:00
40 views | 4 months ago

Considering the optimal treatment strategy for patients with genetically highrisk CLL

Duration: 1:53
113 views | 5 months ago

ALPINE results zanubrutinib vs ibrutinib in CLL

Duration: 0:47
541 views | 1 Jan 2009

Treating CLL in the RR setting switching drug classes and investigational therapies

Duration: 1:49
78 views | 1 month ago

The potential role of noncovalent BTKis in mitigating covalent BTKi resistance

Duration: 1:24
74 views | 1 month ago

An update on the BRAWM trial fixedduration bendamustine rituximab and acalabrutinib in WM

Duration: 4:26
53 views | 1 month ago

241106 Update Leucemia Linfocítica Crónica Webinar FARUPEIB

Duration: 52:30
16 views | 3 weeks ago

Updates on the use of BTKis in the treatment of MCL

Duration: 3:15
35 views | 1 month ago

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

Duration: 2:55
22 views | 2 months ago

Zanubrutinib and acalabrutinib for CLL potential alternatives to ibrutinib

Duration: 3:19
2.3K views | 15 Jun 2019

Genetic testing to risk stratify patients with CLL and aid in treatment decisions

Duration: 2:11
34 views | 1 month ago

Insights into the MAJIC study acalabrutinib venetoclax vs venetoclax obinutuzumab in CLL

Duration: 1:50
731 views | 6 Jul 2022

Zanubrutinib vs Ibrutinib Which BTK Inhibitor Is Better for Waldenström Macroglobulinemia

Duration: 3:55
1 views | 5 months ago

The mutational profile in patients with CLL treated with acalabrutinib or ibrutinib

Duration: 1:34
60 views | 1 month ago

CALQUENCE® acalabrutinib Patient Testimonials Steves Story

Duration: 3:21
46.3K views | 2 months ago

Dr Goy Compares Acalabrutinib With Ibrutinib in MCL

Duration: 0:46
254 views | 9 Apr 2018

Challenges with BTKi cardiotoxicity what can be done to optimize longterm cardiac outcomes

Duration: 2:47
23 views | 1 month ago

How to Treat Chronic Lymphocytic Leukemia CLL with Dr Jeff Sharman Oncology Brothers 2023

Duration: 23:15
3.2K views | 14 Sep 2023

Impact of comorbidities on patient selection for combination therapies in CLL

Duration: 2:01
1 views | 2 months ago

Choosing the best BTK inhibitor for managing CLL

Duration: 1:59
576 views | 23 May 2023

The current role of acalabrutinib in the treatment of CLL

Duration: 1:15
606 views | 4 Oct 2022

Zanubrutinib Extends Remission Time vs Ibrutinib in CLL SLL Dr Jennifer Brown ASH 2023

Duration: 5:45
384 views | 8 months ago

Acalabrutinib And Zanubrutinib in CLL

Duration: 19:32
2K views | 3 Oct 2021